Lumos Diagnostics strengthens U.S. market strategy with new AcuityMD data partnership

Proactive - Interviews for investors

Lumos Diagnostics Chief Commercial officer Paul Kase joined Steve Darling from Proactive to discuss a major step forward in the company’s U.S. commercialization strategy for FebriDx®, its rapid, 10-minute point-of-care test that helps clinicians quickly distinguish between bacterial and non-bacterial respiratory infections. The company has signed a strategic collaboration with U.S. med-tech data platform AcuityMD, a move designed to sharpen visibility into real-world reimbursement patterns and accelerate adoption across key clinical settings. Kase explained that navigating the U.S. reimbursement landscape remains one of the most critical and complex challenges for diagnostic companies. While FebriDx is fast, accurate, and clinically validated, achieving consistent reimbursement from both private and public payers is essential for driving repeat ordering by physicians and expanding market penetration. The new partnership is intended to help Lumos close the often-significant gap between “published” reimbursement rates and actual payments received by clinicians — a common barrier that has historically slowed adoption of innovative diagnostics. The collaboration comes at a pivotal time, as Lumos accelerates its U.S. rollout in partnership with commercial collaborator PRO-spectus, building on strong September-quarter performance and an expanding set of pilot programs across urgent care and primary care networks. AcuityMD’s AI-driven platform integrates data from the Centers for Medicare & Medicaid Services (CMS) and major claims aggregators, covering more than 330 million U.S. patients. By harmonizing national reimbursement data, the platform delivers clear insights into payer-specific behaviour, enabling Lumos to target markets and geographies where reimbursement is most predictable — and to identify gaps where additional education or billing support may be required. Kase noted that this expanded visibility is expected to support more confident ordering among clinicians, reduce administrative uncertainty, and help Lumos drive sustainable, long-term adoption of FebriDx across the U.S. healthcare system. #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #FebriDx #PointOfCare #HealthcareInnovation #MedicalDiagnostics #Reimbursement #AcuityMD #Prospectus #MedTech #USHealthcare #InsuranceClaims #ProactiveInvestors